Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Pharmacoeconomic

Easterbrock P, Beck EJ, Fisher M et al (1998) The use and cost of HIV service provision in England in 1996 Pharmacoeconomics 14 639-652 Edejer TT et al (2003) WHO guide to cost-effectiveness analysis, WHO, Geneva Farnham PG, Gorsky RD (1994) Costs to business for an HIV-infected worker. Inquiry 31 76-88 Flori YA, le VaUlant M (2004) Use and cost of antiretrovirals in France 1995-2000 an analysis based on the medical dossier on human immunodeficiency (release 2) database, Pharmacoeconomics 22 1061-1070... [Pg.371]

Hellinger FJ (2006) Economic models of antiretroviral therapy searching for the optimal strategy, Pharmacoeconomics 24 631-642... [Pg.372]

DiMasi JA, Hansen RW, Grabowski HG. The price of innovation new estimates of drug development costs. Pharmacoeconomics 2003 22 151-85. [Pg.569]

DiMasi JA. The value of improving the productivity of the drug development process faster times and better decisions. In The cost and value of new medicines in an era of change. Pharmacoeconomics 2002 20(Suppl 3) 1-10. [Pg.570]

Quenzer RW, Pettit KG, Arnold RJ, Kaniecki DJ. Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. Am J Manag Care 1997 3 1027-36. [Pg.588]

Bakst A, Meletiche D, Arnold R, et al. The Avandia Worldwide Awareness Registry (AWARe ) an Internet-based program for evaluation of clinical, humanistic and economic outcomes of patients with type 2 diabetes. International Society for Pharmacoeconomics and Outcomes Research Sixth Annual International Meeting. Philadelphia, Pennsylvania, 2001. [Pg.588]

Arnold R, Kotsanos J. Proceedings of the Advisory Panel Meeting and Conference on Pharmacoeconomic Issues Panel 3 Methodological issues in conducting pharmacoeconomic evaluations-retrospective and claims database studies. Value Health 1999 2 82-7. [Pg.589]

Lewis NJ, Patwell IT, Briesacher BA. The role of insurance claims databases in drug therapy outcomes research. Pharmacoeconomics 1993 4 323-30. [Pg.589]

Tarn TY, Dix Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections, Vol. 10, 2004. [Pg.589]

Fletcher AE, Bnlpitt CJ. Pharmacoeconomic evalnation of risk factors for car-diovascnlar disease an epidemiological perspective. Pharmacoeconomics 1992 1 33-44. [Pg.590]

Pharmacoeconomics needs to address all three criteria. One reason is because effectiveness, efficiency and equity are most relevant to economic evaluations another is their intuitive appeal— we are likely to use similar criteria in spending our own personal resources and a third consideration is that they underpin public policy in many countries, including the UK. There will often be tensions between the criteria maximizing effectiveness may well not represent the most efficient use of resources, while efficiency and... [Pg.3]

The validity of pharmacoeconomic data is invariably diminished by two important factors a failure to account for all direct and indirect cost outcomes, and the difficulty of assigning costs to human experiences. In schizophrenia, validity is further reduced by the near-impossibility of conducting trials over several years, or even decades, so as to approach the reality of what is usually a lifelong illness. Given these observations, it would be imprudent to act on the minutiae of data generated in even the best-conducted trials, but it may well be appropriate to draw broad conclusions. [Pg.20]

Like clozapine, risperidone has been subjected to all levels of pharmacoeconomic evaluation. For example, two health-care models have predicted substantial savings resulting from the use of risperidone (Keks, 1997 Davies et al, 1998). [Pg.23]

Pharmacoeconomic evaluations of olanzapine are dominated by data generated from a single company-sponsored clinical trial (Tollefson et al, 1997) and its follow-up. The large number of participants in the trial and its international namre have afforded the opportunity for separate analyses according to country or continent. Whether or not this is a valid approach is debatable. [Pg.27]

Of several randomized, controlled pharmacoeconomic evaluations of olanzapine, all rely on data generated by the large clinical... [Pg.31]

There is little evidence relating to the pharmacoeconomic aspects of the use of quetiapine. In the UK, a retrospective audit of 20 patients (Lee et al, 1998), published only as a conference abstract, tentatively suggested decreased costs for those patients, largely through a reduction in hospital stay and resource use. Quetiapine may also improve quality of life (Hellewell et al, 1999). A large, randomized, controlled pharmacoeconomic evaluation is apparently under way (Drummond et al, 1998) and results are awaited. [Pg.34]

Zotepine has been used in Japan and Germany for many years, but has only recently been marketed in the UK. Zotepine is referred to in two pharmacoeconomic publications (Byrom et al, 1998a, b), but no relevant data are provided. Two evaluations are apparently awaiting publication (Knoll, personal communication, 2001) one a 6-month comparison of zotepine and one a health-care model of outcomes associated with the use of zotepine and haloperidol. [Pg.34]

Considerable funds, time and effort have been expended on pharmacoeconomic evaluation of atypical antipsychotic drugs and many journal... [Pg.35]

At the beginning of this chapter the antagonism between expert methodologists, pharmacoeconomic purists and clinical pragmatists was mentioned. Given the inability to draw conclusive inferences from the data presented here, it would seem that the purists have at least partly been proved correct. [Pg.35]

Almond S, O Donnell O (2000). Cost analysis of the treatment of schizophrenia in the UK a comparison of olanzapine and haloperidol. Pharmacoeconomics 17, 383—9. [Pg.38]

Fitton A, Benfield P (1993). Clozapine an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. [Pg.39]

Ginsberg G, Shani S, Lev B (1998). Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel. Pharmacoeconomics 13,231—41. [Pg.39]

Guest JF, Hart WM. Cookson RF, et al (1996). Pharmacoeconomic evaluation of long-term treatment with risperidone for patients with chronic schizophrenia. Br JMedEcon 10, 59-67. [Pg.40]

Hamilton SH, Revicki DA, Edgell ET, et al (1999). Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia results from a randomised clinical trial. Pharmacoeconomics 15, 469—80. [Pg.40]

Moore DB, Kelly DL, Sherr JD, et al (1998). Rehospitalization rates for depot antipsychotics and pharmacoeconomic... [Pg.40]

Revicki DA (1999). Pharmacoeconomic evaluation of treatments for refractory schizophrenia ... [Pg.41]

Sacristdn JA, G6mez JC, Martin J, et al (1998). Pharmacoeconomic assessment of olanzapine in rhe treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Invest 29—35. [Pg.41]

Spannheimer A, Clouth J, Gregor KJ (1999). Pharmacoeconomic evaluation of the rrearmenr of schizophrenia in Germany a comparison of olanzapine, risperidone and haloperidol using a clinical decision model. Poster presented at the ISPOR Second Annual European Meeting, Edinburgh, November 1999. [Pg.42]

Several analyses are open when considering pharmacoeconomic evaluations of antidepressants (Reeder, 1995 Malek, 1996). [Pg.44]


See other pages where Pharmacoeconomic is mentioned: [Pg.257]    [Pg.371]    [Pg.1]    [Pg.1]    [Pg.2]    [Pg.4]    [Pg.6]    [Pg.8]    [Pg.10]    [Pg.12]    [Pg.14]    [Pg.16]    [Pg.17]    [Pg.18]    [Pg.19]    [Pg.19]    [Pg.39]    [Pg.39]    [Pg.44]    [Pg.44]    [Pg.45]   
See also in sourсe #XX -- [ Pg.141 ]




SEARCH



Applied pharmacoeconomics

Asthma pharmacoeconomics

Clinical trials pharmacoeconomics

Drug therapy pharmacoeconomic evaluation

Economic issues pharmacoeconomics)

INDEX pharmacoeconomics

International Society for Pharmacoeconomics

International Society for Pharmacoeconomics and Outcomes Research

Literature pharmacoeconomic

Pharmaceutical industry pharmacoeconomics

Pharmaceutical products pharmacoeconomic outcomes

PharmacoEconomics

Pharmacoeconomic analysis

Pharmacoeconomic analysis decision-making

Pharmacoeconomic data, reporting

Pharmacoeconomic evaluations

Pharmacoeconomic evaluations comparison

Pharmacoeconomic measure

Pharmacoeconomic research

Pharmacoeconomic trials

Pharmacoeconomic trials Phase

Pharmacoeconomics activity

Pharmacoeconomics adverse drug reactions

Pharmacoeconomics analyses

Pharmacoeconomics analysis perspectives

Pharmacoeconomics and Outcomes Research

Pharmacoeconomics defined

Pharmacoeconomics definition

Pharmacoeconomics demonstrates a drugs value

Pharmacoeconomics economic and humanistic

Pharmacoeconomics in clinical trials

Pharmacoeconomics issues

Pharmacoeconomics limitations

Pharmacoeconomics measures

Pharmacoeconomics outcomes

Pharmacoeconomics outcomes research

Pharmacoeconomics pharmacokinetics

Pharmacoeconomics study design

Schizophrenia pharmacoeconomic comparisons

Schizophrenia pharmacoeconomics

Spain pharmacoeconomics

© 2024 chempedia.info